AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
doxribtimine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 5787 | 50-89-5 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Doxribtimine is approved in combination with doxecitine under the name KYGEVVI. The primary mechanism of action of doxecitine and doxribtimine is the incorporation of nucleosides deoxycytidine (dC) and deoxythymidine (dT) into skeletal muscle mitochondrial deoxyribonucleic acid (DNA) to restore mitochondrial DNA copy number and improve skeletal muscle function in patients with TK2d. Doxecitine and doxribtimine likely utilize residual TK2 activity as well as cytosolic phosphorylation pathways such as thymidine kinase 1 and deoxycytidine kinase to increase mitochondrial DNA precursors deoxycytidine triphosphate and deoxythymidine triphosphate in the mitochondria.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 26, 2026 | EMA | UCB Pharma | |
| Nov. 3, 2025 | FDA | UCB Inc |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A16AX29 | ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Various alimentary tract and metabolism products |
| CHEBI has role | CHEBI:25212 | metabolite |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
Related Drugs by ATC class:
A16AX Various alimentary tract and metabolism products 23 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Thymidine kinase 2 deficiency | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 2GM/PACKET;2GM/PACKET | KYGEVVI | UCB INC | N219792 | Nov. 3, 2025 | RX | FOR SOLUTION | ORAL | 10471087 | Aug. 7, 2036 | TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS |
| 2GM/PACKET;2GM/PACKET | KYGEVVI | UCB INC | N219792 | Nov. 3, 2025 | RX | FOR SOLUTION | ORAL | 11649259 | Aug. 19, 2040 | TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 2GM/PACKET;2GM/PACKET | KYGEVVI | UCB INC | N219792 | Nov. 3, 2025 | RX | FOR SOLUTION | ORAL | Nov. 3, 2030 | NEW CHEMICAL ENTITY |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Thymidine kinase | Kinase | IC50 | 5.39 | CHEMBL | |||||
| Thymidylate kinase | Kinase | Ki | 4.57 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| THM | PDB_CHEM_ID |
| CHEMBL52609 | ChEMBL_ID |
| C000732039 | MESH_SUPPLEMENTAL_RECORD_UI |
| DB04485 | DRUGBANK_ID |
| C0040077 | UMLSCUI |
| CHEBI:17748 | CHEBI |
| 11756 | INN_ID |
| D12466 | KEGG_DRUG |
| 5789 | PUBCHEM_CID |
| 44508 | MMSL |
| d10336 | MMSL |
| 005774 | NDDF |
| 4718 | IUPHAR_LIGAND_ID |
| VC2W18DGKR | UNII |
| 1372538 | RXNORM |
| D013936 | MESH_DESCRIPTOR_UI |
| VC2W18DGKR | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| KYGEVVI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 50474-350 | POWDER, FOR SOLUTION | 2 g | ORAL | NDA | 28 sections |